1. Germany Stocks

  2. •

    Health technology

  3. •

    Medical specialties
STRATEC SE

STRATEC SE

23.90
EUR
+0.85
(+3.69%)
-0.03EPS
204.46MMarket Cap
Nov 12Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
10.89
12.31
12.44
15.6
17.46
15.73
17.86
20.73
23.73
22.64
22.25
21.19
20.64
20.14
Basic EPS, GAAP
1.32
1.68
1.87
1.65
2.16
0.75
1.2
2.09
3.3
2.41
1.26
1.32
-0.02
-0.03
Free Cash Flow per Basic Share
1.17
2.81
1.45
0.53
1.2
-0.63
-0.47
0.52
3.57
-0.72
0.16
2.51
-1.37
1.77
Dividend per Share
0.56
0.6
0.7
0.75
0.77
0.8
0.82
0.84
0.9
0.95
0.97
0.55
0.6
- -
Book Value per Share
8.26
9.51
10.92
12.01
13.25
12.72
13.22
14.26
16.97
18.65
19.5
19.95
19.52
19.61
Tangible Book Value per Share
5.7
6.94
8.3
1.99
3.95
4.51
5.15
6.94
9.6
11.5
10.25
10.58
10.64
10.37
Basic Weighted Avg Shares
12
12
12
12
12
12
12
12
12
12
12
12
12
12
Sales/Revenue/Turnover
128
145
147
185
207
188
214
250
287
275
270
258
251
245
Operating Margin (%)
15.23
16.6
18.3
13.05
11.76
8.19
8.5
13.62
17.56
15.57
10.78
10.94
4.26
4.32
Depreciation Expense
7
8
6
11
18
22
19
23
18
17
18
19
25
25
Net Income, GAAP
15
20
22
19
26
9
14
25
40
29
15
16
- -
- -
Effective Tax Rate (%)
19.94
17.82
18.73
14.66
8.29
21.15
13.47
13.89
14.68
25.24
28.66
27.2
104.99
106.78
Profit Margin (%)
12.1
13.65
15.03
10.54
12.36
4.78
6.74
10.07
13.91
10.64
5.68
6.22
-0.1
-0.16
Working Capital
57
74
89
12
88
88
93
121
142
152
138
133
160
151
LT Debt
7
4
4
3
62
69
90
104
79
80
94
86
108
- -
Total Equity
97
112
129
142
158
152
159
173
206
227
237
243
237
238
Return on Invested Capital (%)
15.33
17.25
16.77
11.73
12.55
5.19
6.57
10.88
14.55
10.36
5.8
5.14
-0.14
-0.3
Return on Capital (%)
15.52
17.58
17.19
11.62
12.15
4.29
6.45
9.78
14.37
10.13
5.26
5.41
-0.12
-0.26
Return on Common Equity (%)
16.76
18.9
18.3
14.36
17.08
5.79
9.28
15.19
21.12
13.52
6.63
6.68
-0.1
-0.17

Capital Structure

EUR

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
25
- -
- -
LT Borrowings
99
- -
- -
LT Finance Leases
9
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
12
12
12
Market Capitalization
275
210
204

Working Capital

EUR

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
213
197
198
Cash, Cash Equivalents & STI
24
25
21
Accounts Receivable, Net
57
43
46
Inventories
110
114
112
Total Current Liabilities
54
45
47
Payables & Accruals
- -
- -
- -
ST Debt
25
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

EUR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
6.45%
6.83%
-2.15%
Free Cash Flow
129.3%
323.67%
-154.59%
Net Income, GAAP
-2.27%
-22.56%
-101.51%
Sales/Revenue/Turnover
6.1%
0.32%
-2.62%
Total Cash Common Dividend
0.25%
-3.66%
9.06%

Quarterly Revenue

EUR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
51
68
60
81
258
2025
60
58
57
75
251
2026
53
59
- -
- -
- -

Quarterly Earnings Per Share

EUR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.04
0.29
0.06
0.95
1.32
2025
0.12
0.1
0.12
-0.36
-0.02
2026
-0.14
0.34
- -
- -
- -

Quarterly Dividends Per Share

EUR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.55
2025
- -
- -
- -
- -
0.6
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Marcus Wolfinger
Full Time Employees
1,403
Sector
Health technology
Industry
Medical specialties
Address
Gewerbestrasse 37 Birkenfeld RP Germany 75217
IPO Date
Aug 25, 1998
Website
stratec.com
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
Stratec SE specializes in designing and manufacturing fully automated analyzer systems, software, and complex consumables for clinical diagnostics, in vitro diagnostics (IVD), and biotechnology applications. The company's core product offerings include automated analyzer systems for molecular diagnostics, immunoassays, hematology, and transfusion diagnostics; integrated laboratory software and middleware solutions for data management and system control; smart consumables including sample preparation solutions and complex reagents; and system software that supports diagnostic workflows. Stratec operates primarily as an original equipment manufacturer (OEM) supplying well-known global diagnostic companies, with its products used by clinical laboratories, blood banks, and research institutes worldwide. Founded in 1979 and headquartered in Birkenfeld, Germany, the company has expanded its geographic focus to include growing operations and sales channels in the United States, Asia-Pacific, and Europe. Recent major developments include the strengthening of its development pipeline through new cooperation agreements, such as a comprehensive strategic partnership in immunodiagnostics aimed at enhancing and extending product lifecycles. Stratec completed the final development milestone for a customer-focused product line in transfusion diagnostics in 2024 and advanced several projects involving complex consumable production in the US. The company has increased its local presence in key growth markets by establishing new sales and production units in Asia and expanding distribution channels in the United States post its integration of Natech Group, creating cross-selling opportunities across the group. In 2024, Stratec reported resilient sales of €257.6 million with an adjusted EBIT margin improvement to 13.0%, driven by strong service parts and consumables sales alongside licensing and development revenues. Operational efficiency measures and structural changes contributed to margin enhancement despite pandemic-related demand disruptions and elevated customer inventory levels. These strategic initiatives and operational improvements underscore the company’s continued focus on innovation, global expansion, and long-term partnerships within the diagnostics industry.